行情

LPCN

LPCN

Lipocine
NASDAQ

实时行情|Nasdaq Last Sale

0.4700
-0.0400
-7.84%
盘后: 0.4700 0 0.00% 18:17 01/24 EST
开盘
0.5295
昨收
0.5100
最高
0.5340
最低
0.4600
成交量
140.84万
成交额
--
52周最高
3.450
52周最低
0.3200
市值
1,193.89万
市盈率(TTM)
-0.8553
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

LPCN 新闻

  • 波音777X完成首飞:明年起开始交付 未来世界最大客机
  • IT之家.3小时前
  • 瑞幸咖啡捐赠1000万元 助力疫情防控
  • 新浪科技.3小时前
  • 法国撤侨方案:大巴先送至长沙隔离14日
  • 观察者网.4小时前
  • 贝索斯手机遭入侵 手机窃听再次成为焦点
  • 新浪科技.4小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

LPCN 简况

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
展开

Webull提供Lipocine Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。